CE15 - Immunologie, Infectiologie et Inflammation

Elucidating the role of secretory leukocyte protease inhibitor in Sjögren syndrome. – SLIPSS

Submission summary

Sjögren's syndrome (SjS) is a chronic autoimmune disease characterized by the destruction of exocrine glands by self-reactive immune cells. About 0.5% of the population is affected with dry mouth and eyes and there is no cure against the disease. The immunopathology of SjS is complex and associated with an intricate crosstalk between various cell types including salivary gland epithelial cells (SGECs), lymphocytes, and innate immune cells. Recent research in the field of autoimmunity, revealed the critical role of antimicrobial peptides (AMPs) in preventing these diseases via their strong immunoregulatory capacity. Among them the secretory leukocyte protease inhibitor (SLPI) is highly expressed by the acinar cells in the SGs. SLPI present in the extracellular milieu can penetrate neighboring cells and modulate the function of various immune cells. Our objective is therefore to determine the role of SLPI in the exocrine glands during the development of SjS in murine models and using patient samples. Our project will provide new perspectives in the immunopathology of SjS and could offer new therapeutic opportunities.

Project coordination

Julien DIANA (Institut National de la Santé et de la Recherche Médicale)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.


INSERM - UMR 1151 Institut National de la Santé et de la Recherche Médicale
INSERM - IMVA-HB Institut National de la Santé et de la Recherche Médical
INSERM - UMR 1151 Institut National de la Santé et de la Recherche Médicale

Help of the ANR 652,124 euros
Beginning and duration of the scientific project: January 2023 - 42 Months

Useful links

Explorez notre base de projets financés



ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter